New oral anticoagulants vs vitamin K antagonists: Benefits for health-related quality of life in patients with atrial fibrillation

International Journal of Medical Sciences

Volumn 11, Issue 7, 2014, Pages 680-684

  Alegret, Josep M ^a   Viñolas, Xavier ^b   Arias, Miguel A ^c   Martínez Rubio, Antoni ^d   Rebollo, Pablo ^e   Ràfols, Carles ^f   Martínez Sande, José L ^g  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b Hospital de la Sta Creu i St Pau ^*  (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d Parc Taulí Hospital Universitari   (Spain)

^e BAP LA SER Outcomes   (Spain)

^f I3 Research   (Spain)

^g University Hospital of Santiago de Compostela   (Spain)

Author keywords

Dabigatran; Health related quality of life; New oral anticoagulants; Ribaroxaban; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; VITAMIN K GROUP;

ADAPTATION; ADULT; AGE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CHADS2 SCORE; COHORT ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; EMBOLISM; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SATISFACTION; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; VENTRICULAR DYSFUNCTION, LEFT; VITAMIN K;

EID: 84899708008     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8916     Document Type: Article

References (17)

1. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am CollCardiol. 2010; 55: 2308-2316.
2. Connolly SJ, Ezekowitz D, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke Wet al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
5. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am CollCardiol 2013; 61: 1998-2006.
6. Providência R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-35.
7. Sánchez González R, Yanes Baonza M, Cabrera Majada A, Ferrer García-Borrás JM, Alvarez Nido R, Barrera Linares E. Adaptación transcultural de un cuestionario para medir la calidad de vida de los pacientes con anticoagulación oral. Aten Primaria 2004; 34: 353-359.
8. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999; 281: 145-50.
9. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, de Mol BJ, Prins MH, Hutten BA et al. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J ThrombHaemost 2004; 2: 584-591.
10. Cromheecke ME, Levi M, Colly LP, de Mol BJ, Prins MH, Hutten BA et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000; 356: 97-102.
11. Siebenhofer A, Hemkens LG, Rakovac I, Spat S, Didjurgeit U. Self-management of oral anticoagulation in elderly patients-effects on treatment-related quality of life. Thromb Res 2012; 130: e60-66.
12. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al; the ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
13. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH et al; on behalf of the BAFTA investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007; 370: 493-503.
14. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
15. Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study. Int J Cardiol 2013; 168: 2540-7.
16. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014 [Epub ahead of print].
17. Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. ClinGastroenterolHepatol 2013; 11: 246-52.